Cryo-Cell International Q3 2024 Earnings Report

Cryo-Cell International EPS Results

• Actual EPS: $0.13
• Consensus EPS: $0.02
• Beat/Miss: Beat by +$0.11
• One Year Ago EPS: N/A

Cryo-Cell International Revenue Results

• Actual Revenue: $8.07 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cryo-Cell International Announcement Details

• Quarter: Q3 2024
• Date: 10/15/2024
• Time: TAS
• Conference Call Date: Tuesday, October 15, 2024
• Conference Call Time: 8:00AM ET

Cryo-Cell International (NYSEAMERICAN:CCEL), Inc. is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth. Trained medical personnel coordinate with healthcare providers to collect cord blood and cord tissue immediately after delivery. Samples are shipped in temperature-controlled containers to Cryo-Cell’s processing laboratories, where stem cell fractions are isolated, tested for purity and viability, and ultimately cryogenically stored in liquid nitrogen tanks.

Cryo-Cell serves families across the United States and in select international markets through a network of distribution partners. In addition to its core storage offerings, the company provides customized preservation plans, educational materials and dedicated client support to prospective parents. Cryo-Cell also collaborates with research institutions and participates in industry initiatives aimed at expanding the therapeutic applications of cord blood and tissue derivatives.

Guided by an experienced management team with expertise in biotechnology, clinical operations and regulatory affairs, Cryo-Cell International continues to invest in advanced processing technologies and service expansion. The company’s focus on safety, compliance and customer engagement positions it as a leading player in the evolving field of regenerative medicine and stem cell banking.